---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116008"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:39:55.853915+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q3 net loss $32.7M, appoints Brent Pfeiffenberger CEO

## Summary
- Brent Pfeiffenberger appointed CEO effective Dec 4, 2023; Greg Russotti becomes Chief Technology and Manufacturing Officer.
- Cash and investments $284.3M as of Sep 30, 2023; cash runway into 2026.
- Q3 2023 net loss $32.7M vs $30.7M in Q3 2022; R&D expenses down to $22.8M from $25.9M.
- Expanded license with FUJIFILM Cellular Dynamics for iPSC-derived cell therapies in autoimmune/inflammatory diseases.
- Initial Phase 1 ELiPSE-1 data for CNTY-101 in B-cell lymphomas to be presented at ASH Dec 2023.

## SEC filing metadata
- accession: 0001104659-23-116008
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465923116008/0001104659-23-116008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465923116008/tm2330170d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116008
- JSON: https://secwatch.observer/filing/0001104659-23-116008.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116008.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $0.1 million, net income $32.7 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $0.1 million
  - Net income: $32.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: (BMS) collaboration of $118.5 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option, and license agreement with BMS was $0.1 million for the three months ended September 30, 2023 compared to $2.2 million for the same period in 2022. Revenue recognized under the collaboration agreement fluctuates based on the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465923116008/0001104659-23-116008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.